KOSDAQBiotech & Pharma018620

WooGeneB&GCO

₩2,605▼ 3.87%2026-11-18 close
Market Cap
₩18.1B
Turnover
₩37,705,075
Volume
10K
Shares out.
6.9M
PER
—
PBR
0.6×
EPS
-₩380
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Animal health maker: profitable and loss-making quarters coexist

WooGeneB&GCO makes animal medicines and vaccines; its 2025 annual operating profit of KRW 319 million edged up, but after a Q2 2026 return to profit it posted an operating loss of KRW 144 million in Q3 2026.

  1. 1

    Revenue peaked at KRW 57.9 billion in 2023, then fell to KRW 55.7 billion in 2024 and KRW 54.8 billion in 2025, two straight years of decline.

  2. 2

    2025 operating profit was KRW 319 million (up 8.1% year on year), but the operating margin was only 0.6%, and the controlling shareholders' net loss of KRW 1.77 billion extends a three-year run of losses since 2023.

  3. 3

    Q2 2026 returned to profit with operating profit of KRW 1.38 billion and controlling shareholders' net income of KRW 1.15 billion, but Q3 2026 swung to an operating loss of KRW 144 million and a controlling net loss of KRW 946 million.

  4. 4

    At year-end 2025 the debt ratio was 70.5%, and controlling shareholders' equity of KRW 30.8 billion is below half of total equity of KRW 63.9 billion, which leaves a large non-controlling interest.

  5. 5

    Convertible bonds were fully repaid in March 2026, and trading resumed on May 21, 2026 after the 5-to-1 par value consolidation was listed as a changed security.

02

Business structure

WooGeneB&GCO is a KOSDAQ-listed maker of animal medicines and vaccines. According to the 2025 annual report filed in March 2026, domestic sales accounted for 82% of 2025 revenue and exports for 18%.

The company says its penicillin-based injectable Antipen SM and the Supertia and Denagard series have established themselves as prescription treatments in Korea.

It supplies products through more than 20 major distribution channels domestically and is widening its overseas sales network in the United States, Hong Kong and Southeast Asia.

In vaccines, the porcine epidemic diarrhea vaccine IMMUNIS PED-M is the lead export item, with its first shipments to Thailand recorded in December 2023.

In October 2023 the company launched a combined swine fever and swine erysipelas vaccine, and in November 2024 it signed a supply contract with the Ministry of Agriculture, Food and Rural Affairs for a lumpy skin disease vaccine.

Media reports for the first half of 2026 said PED-M shipments to Thailand, adjuvant sales in South America and Russia/CIS, and growth of a swine respiratory treatment in Southeast Asia contributed to higher sales.

The subsidiary OSP, in which the company took a stake in December 2019, has seen its private-brand business expand, which helped profits. Because shipments depend on domestic livestock disease outbreaks and government stockpiling, quarterly revenue swings tend to be large. Overseas expansion also depends on obtaining product approval in each country first.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩13.2B-₩800M−5.8%
2025Q4₩13.5B₩500M3.4%
2026Q1₩14.3B₩700M4.9%
2026Q2₩15.5B₩1.4B8.9%
2026Q3₩12.7B-₩100M−1.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩43.7B₩1.2B₩800M2.6%2.4%41.7%
2023₩57.9B₩700M-₩1.2B1.2%−3.5%68.1%
2024₩55.7B₩300M-₩5.2B0.5%−18.8%62.6%
2025₩54.8B₩300M-₩1.8B0.6%−5.8%70.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 43.7 billion in 2022 to KRW 57.9 billion in 2023 (up 32.5%), the largest year in the 2022–2025 span, and then fell two straight years to KRW 55.7 billion in 2024 (down 3.9%) and KRW 54.8 billion in 2025 (down 1.6%).

Operating profit was KRW 1.16 billion in 2022, the largest year, and declined to KRW 714 million in 2023 (down 38.2%) and KRW 295 million in 2024 (down 58.6%), the smallest year. In 2025 operating profit rose 8.1% to KRW 319 million, but the operating margin was only 0.6%, against 2.6% in 2022.

The margin path ran 2.6% in 2022, 1.2% in 2023, 0.5% in 2024 and 0.6% in 2025. Controlling shareholders' net income of KRW 850 million in 2022 turned into a controlling net loss of KRW 1.18 billion in 2023, widened to a net loss of KRW 5.22 billion in 2024, and narrowed to a net loss of KRW 1.77 billion in 2025.

Net income including non-controlling interests was a net loss of KRW 3.58 billion in 2025, and the gap with the controlling figure suggests non-controlling holders absorbed part of the loss.

The debt ratio climbed from 41.7% in 2022 to 70.5% in 2025, and operating cash flow was KRW 2.64 billion, KRW 1.18 billion, KRW 6.7 billion and KRW 3.87 billion across 2022 to 2025.

Quarterly, revenue of KRW 13.2 billion and an operating loss of KRW 769 million in Q3 2025 gave way to Q4 2025 revenue of KRW 13.5 billion (up 2.0% quarter on quarter) and operating profit of KRW 459 million, a swing to profit.

Q1 2026 revenue was KRW 14.3 billion (up 6.1%), operating profit KRW 705 million (up 53.6%), and the controlling net loss narrowed to KRW 23.78 million. Q2 2026 revenue reached KRW 15.5 billion (up 8.3%), operating profit KRW 1.38 billion (up 95.6%), and controlling net income KRW 1.15 billion, a return to profit.

Q3 2026 revenue fell to KRW 12.7 billion (down 18.1% quarter on quarter and down 4.1% year on year), with an operating loss of KRW 144 million and a controlling net loss of KRW 946 million. The controlling net losses over the last four quarters (Q4 2025 to Q3 2026) total KRW 2.59 billion.

05

Industry analysis

The animal medicine market is strongly shaped by livestock disease outbreaks and government disease-control policy. Demand for swine vaccines is steady at the farm level, but timing of outbreaks and government supply volumes can make quarterly revenue volatile.

The company's results appear to reflect this pattern: revenue rose in Q1 and Q2 2026 but fell 18.1% quarter on quarter in Q3. The export markets the company has named are Southeast Asia, Latin America, and Russia and the CIS.

Overseas sales depend on local product approval, so the speed of approvals is a key variable for export growth. The company has said exports to markets such as Vietnam and Mexico would expand once PED-M approval is completed there.

Although classified under biotech and pharmaceuticals, the company differs from listed firms centered on human medicines because most of its revenue depends on the livestock market. Benchmarking against animal health peers therefore explains its results better than comparing it with human drug developers.

Because it combines in-house vaccines with animal medicines, margins shift with product mix. The operating margin of 0.6% in 2025 can be read in this context of structurally thin margins. The company names new vaccines and its pet food business as its next growth drivers.

06

Outlook

The company said it will focus its resources in the second half of 2026 on launching high value-added vaccines and new bio projects. It also cited global expansion of its premium pet food business and a new vaccine lineup as growth drivers.

It said PED-M exports would increase once approvals are completed in markets such as Vietnam and Mexico. No approval timing has been disclosed, so it is difficult to pin down when such exports would appear in results.

On the financing side, the fifth convertible bond series was fully repaid in March 2026, reducing the overhang of potential sales. The largest shareholder side disclosed open-market purchases of company shares worth about KRW 1 billion.

A margin loan held by a former CEO was fully repaid, lowering risk tied to the largest shareholder's stake. At the March 2026 annual shareholder meeting, amendments to the articles, the re-election of an executive director and the appointment of an outside director were approved.

A company official said the business should gradually be re-rated as profitability recovers from the recent improvement. That remark reflects the company's expectation, while the disclosed figures show a return to an operating loss in Q3 2026.

The next checkpoint is the 2026 annual report, which will show Q4 2026 results and the full-year operating margin. The timing of new product launches and overseas approvals should be checked against company disclosures and news reports once dates are confirmed.

07

Valuation

PER
—
PBR
0.6×
ROE
-8.9%
EPS
-₩380
BPS
₩4,462
Dividend per share
₩0

Because the controlling shareholders' net loss over the last four quarters persists, a price-to-earnings multiple cannot be calculated. The price-to-book ratio is below 1x, and reports put it at about 0.9x in 2024 and about 0.8x in 2025. Over those two years the shares have traded at a low multiple of net assets.

Controlling shareholders' equity is less than half of total equity, so asset value analysis must also account for the size of non-controlling interests. The cash dividend yield is effectively 0%, so a dividend-based valuation is difficult to build.

Price volatility also matters: in July 2026 the stock was designated as a KRX investment-caution issue after a sharp rise and concentrated buying by a small number of accounts.

Because results have alternated between losses and profits since 2025, the earnings base used for multiples keeps shifting, which complicates interpretation. The 5-to-1 par value consolidation changed the per-share price structure, so direct comparison with past share prices is not meaningful. Valuation rests on whether operating profit can stay in the black on a sustained basis.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Wider export channels

Media reports said PED-M shipments to Thailand, adjuvant sales in South America and Russia/CIS, and growth of a swine respiratory treatment in Southeast Asia lifted first-half 2026 sales. The company said exports would expand once PED-M approval is completed in Vietnam and Mexico.

Overseas sales were 18% of 2025 revenue, leaving room to raise the export share from a domestically centered base.

Recent quarterly profit recovery

After an operating loss of KRW 769 million in Q3 2025, the company returned to operating profit of KRW 459 million in Q4 2025. Operating profit reached KRW 1.38 billion in Q2 2026, and KRW 705 million in Q1 2026 was up 53.6% on the prior quarter. Full-year 2025 operating profit rose 8.1% to KRW 319 million.

Lower financing burden

The fifth convertible bond series matured and was repaid in March 2026, reducing the overhang of potential sales. A former CEO's margin loan secured by shares was fully repaid, lowering risk tied to the largest shareholder's stake.

09

Bear factors

Two years of revenue decline

Quarterly revenue reached KRW 15.5 billion in Q2 2026 but dropped to KRW 12.7 billion in Q3, down 18.1% quarter on quarter and down 4.1% year on year. Sustained top-line growth has yet to be demonstrated.

Thin margins and three years of losses

The operating margin fell from 2.6% in 2022 to 0.6% in 2025. Controlling shareholders' losses persisted for three years from 2023 to 2025, and the controlling net losses over the last four quarters total KRW 2.59 billion. Q3 2026 returned to an operating loss of KRW 144 million.

Balance sheet and share price volatility

The debt ratio rose from 41.7% in 2022 to 70.5% in 2025, with total liabilities of KRW 45.1 billion at year-end 2025. In July 2026 the stock was designated as a KRX investment-caution issue after a three-day rally and concentrated buying by specific accounts. Most reports give the designation date as July 10, 2026, while one outlet reported July 13.

10

Risk factors

Earnings volatility

Quarterly operating results have swung between a profit in Q2 2026 and a loss in Q3. Revenue depends on livestock disease outbreaks and government supply volumes, which makes quarterly results hard to forecast.

Controlling net losses totaling KRW 2.59 billion over the last four quarters add pressure on earnings continuity.

Overseas approvals and export dependence

Export sales were 18% of 2025 revenue, and export growth depends on product approvals in each country. Approval completion timing in markets such as Vietnam and Mexico has not been disclosed, which makes the timing of earnings effects uncertain. Concentration in particular overseas markets would expose results to local policy changes.

Governance and capital structure

Controlling shareholders' equity is KRW 30.8 billion out of total equity of KRW 63.9 billion, so non-controlling interests are large. Convertible bonds with a KRW 7 billion face value issued by a subsidiary appear in the year-end 2025 consolidated notes, which makes the group structure complex.

The largest shareholder side holds 30.91% of shares, and an outside director resigned in March 2026, changing the board composition.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    This is the close of Q4 2026. Whether operating profit returns to the black after the Q3 operating loss of KRW 144 million will show whether the quarterly profit recovery holds.

  2. March 31, 2027 (annual report filing deadline)

    The 2026 annual report will show whether revenue moved from KRW 54.8 billion in 2025, whether the operating margin improved from 0.6%, and whether controlling shareholders' results extend losses or turn to profit.

  3. March 2027 (expected annual general meeting)

    The annual general meeting may show dividend decisions and board changes. Whether the cash dividend yield stays near zero will be the key point for shareholder returns.

  4. After December 2026 (timing not set)

    Completion of PED-M approvals in Vietnam, Mexico and other markets is the item to watch. If approvals are completed, export growth the company has described could start to appear in results.

12

Overall view

WooGeneB&GCO mainly sells animal medicines and vaccines. Its revenue fell two straight years from KRW 57.9 billion in 2023 to KRW 54.8 billion in 2025. Operating profit rose 8.1% to KRW 319 million in 2025, but the operating margin stayed at 0.6%.

Controlling shareholders' losses have continued for three years since 2023.

Quarterly results in 2026 have alternated between profit and loss: Q2 returned to operating profit of KRW 1.38 billion and controlling net income of KRW 1.15 billion, while Q3 swung to an operating loss of KRW 144 million and a controlling net loss of KRW 946 million.

On the financing side, the March 2026 repayment of convertible bonds and the full repayment of a margin loan tied to the largest shareholder reduced latent risks. Against that, the debt ratio rose to 70.5% and controlling equity is below half of total equity.

Export growth depends on the timing of overseas approvals such as PED-M. The next checkpoint is the 2026 annual report, which will disclose Q4 and the full-year operating margin.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. kind.krx.co.kr
  3. view.asiae.co.kr
  4. hankyung.com
  5. saramin.co.kr
  6. news.nate.com
  7. smarttoday.co.kr
  8. markets.hankyung.com
  9. view.nate.com
  10. digitaltoday.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. topstarnews.net
  15. topstarnews.net
  16. topstarnews.net
  17. topstarnews.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis